Novocaine

• Antiarrhythmic Agents
• ATC:C01BA02

• Biocoryl
• Novocainamid
• Novocainamide
• Novocaine Amide
• Novocamid
• Procainamide Hcl
• Procaine Amide
• Procamide
• Procan
• Procan Sr
• Procanbid
• Procapan
• Promine
• Pronestyl
• Pronestyl-Sr

• No information avaliable

C₁₃H₂₁N₃O

http://www.rxlist.com/cgi/generic3/procain.htm

Novocaine MSDS

Shannon SK et al., J Comb Chem. 2003 Nov-Dec;5(6):860-8

235.325 g/mol

165-169 ^oC

5050 mg/L

Solid

1.282

Capsule; Liquid; Solution; Tablet (extended-release)

For the treatment of life-threatening ventricular arrhythmias.

Procainamide is an agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Procainamide appears to be similar to that of procaine and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected.

75 to 95%

LD₅₀=95 mg/kg (rat, IV); LD₅₀=312 mg/kg (mouse, oral); LD₅₀=103 mg/kg (mouse, IV); LD₅₀=250 mg/kg (rabbit, IV)

The patient should be encouraged to disclose any past history of drug sensitivity, especially to procaine or other local anesthetic agents, or aspirin, and to report any history of kidney disease, congestive heart failure, myasthenia gravis, liver disease or lupus erythematosus.

The patient should be counseled to report any symptoms of arthralgia, myalgia, fever, chills, skin rash, easy bruising, sore throat or sore mouth, infections, dark urine or icterus, wheezing, muscular weakness, chest or abdominal pain, palpitations, nausea, vomiting, anorexia, diarrhea, hallucinations, dizziness or depression.

Humans and other mammals